Abstract： Objective： To explore the interventional effect of gypenosides on liver lipid metabolism in non-alcoholic fatty liver disease mice based on lipidomics technology. Method：A high-fat diet was used to induce a mouse model (n=24) of non-alcoholic fatty liver disease for 14 weeks. Starting from the eleventh week of modeling，they were randomly divided into model group，gypenosides group and obeticholic acid group， and administered by gavage for 4 weeks. Eight mice were given normal control feed as a normal group. Observe the content of triglycerides (TG) in the liver and the pathological changes in liver tissue [HE staining and calculate the non-alcoholic fatty liver disease Activity Score (NAS)]，changes of serum alanine aminotransferase (ALT)， aspartate aminotransferase (AST)， total cholesterol (TC)， TG， low- density lipoprotein cholesterol (LDL- C)， high- density lipoprotein cholesterol (HDL- C) ， fasting blood glucose ， fasting insulin and insulin resistance index. Application of liquid chromatography-mass spectrometry (LC- MS) was used to detect lipid metabolism in mouse liver. Results：The steatosis of liver tissue in the model group was significant. The TG and NAS scores of liver tissue，serum ALT，AST，TC，TG，LDL-C， fasting blood glucose，fasting insulin，and insulin resistance index were significantly higher than those in the normal group (P＜0.05). The pathological changes of liver tissue in the gypenosides group and the obeticholic acid group were significantly reduced，and the TG and NAS scores of liver tissue，serum AST， ALT， TC， fasting blood glucose， fasting insulin， and insulin resistance index were significantly reduced compared to the model group (P＜0.05). Lipidomics results showed that after intervention with gypenosides，there were significant changes in 17 liver lipid metabolism in non-alcoholic fatty liver disease mice， including FA， MGDG， PA， PC， PE， PS， LPE， LPC， and SM， etc. Conclusion： Gypenosides can improve lipid metabolic disorders in non-alcoholic fatty liver disease.